Ipamorelin

Ipamorelin is a pentapeptide classified as a ghrelin mimetic or growth hormone secretagogue (GHS). It is designed to stimulate the release of growth hormone (GH) from the pituitary gland. Unlike some other GHS, Ipamorelin is often described as having a more selective action, primarily targeting GH release without significantly impacting cortisol or prolactin levels at typical dosages. Its mechanism of action involves binding to the ghrelin receptor (also known as the growth hormone secretagogue receptor 1a, or GHS-R1A), mimicking the effects of the endogenous hormone ghrelin. This binding triggers a cascade of events within the pituitary gland, ultimately leading to increased GH secretion.

The current research landscape surrounding Ipamorelin is relatively limited, particularly in human clinical trials. While preclinical studies and some human trials have been conducted, it has not been approved by the FDA for any therapeutic indication. A Phase 2 clinical trial sponsored by Helsinn Therapeutics (U.S.), Inc., investigated the safety and efficacy of Ipamorelin compared to placebo for the recovery of gastrointestinal function post-surgery, enrolling 320 participants and reaching completion. Another Phase 2 trial by the same sponsor examined the safety and efficacy of Ipamorelin for the management of post-operative ileus, with 117 participants. The results of these trials are not readily available in the public domain, hindering a comprehensive assessment of its clinical effectiveness.

Published research papers offer some insights into Ipamorelin's potential effects. A review article in *Translational Andrology and Urology* discussed the role of growth hormone secretagogues, including Ipamorelin, in managing body composition in hypogonadal males. Other studies have explored its effects on nociception (*Journal of Experimental Pharmacology*), the hypothalamic-pituitary-testicular axis in fish (*Animal Reproduction Science*), and its potential use in positron emission tomography imaging of the ghrelin receptor (*European Journal of Medicinal Chemistry*). One study in *Physiology & Behavior* found that Ipamorelin inhibited cisplatin-induced weight loss in ferrets and exhibited anti-emetic effects. It is important to note that several of these papers have received few or no citations, suggesting a limited impact on the broader scientific community.

The safety profile of Ipamorelin, based on available data, appears to be relatively benign, although further research is needed. The FDA adverse event reporting system (FAERS) contains a small number of reports associated with Ipamorelin, with no serious adverse events reported. The most common reactions included recalled product administered, rash, arthralgia, increased blood HIV RNA, and increased blood pressure. However, the FAERS data should be interpreted with caution, as it reflects spontaneous reports and does not establish causality.

From a regulatory standpoint, Ipamorelin is currently unregulated in many jurisdictions. It is not FDA-approved and is categorized as a Category 2 substance, meaning it is banned from compounding by pharmacies. This lack of regulatory oversight raises concerns about product quality, purity, and dosage accuracy.

Ipamorelin is often used by individuals seeking anti-aging benefits, muscle growth, and improved sleep quality. These users typically obtain the peptide through online vendors or compounding pharmacies, often without a prescription. The appeal stems from its perceived ability to increase growth hormone levels without the potential side effects associated with direct GH administration or other less selective GHS. However, the lack of robust clinical evidence supporting these uses and the unregulated nature of the product pose significant risks to consumers.

Given the limited clinical trial data, the small number of adverse event reports, and its unregulated status, further rigorous research is needed to fully understand the efficacy, safety, and long-term effects of Ipamorelin before it can be considered a safe and effective therapeutic agent.